RAB27B expression in pancreatic cancer is predictive of poor survival but good response to chemotherapy.
Exosomes
RAB27B
chemotherapy
pancreatic cancer
treatment response
Journal
Cancer biomarkers : section A of Disease markers
ISSN: 1875-8592
Titre abrégé: Cancer Biomark
Pays: Netherlands
ID NLM: 101256509
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
8
8
2023
pubmed:
30
5
2023
entrez:
30
5
2023
Statut:
ppublish
Résumé
Pancreatic cancer is the 4th leading cause of cancer-related death with poor survival even after curative resection. RAB27A and RAB27B are key players in the exosome pathway where they play important roles in exosome secretion. Evidence suggests that RAB27A and RAB27B expression not only leads to tumor proliferation and invasion, but also plays an important role in antigen transfer necessary for anticancer immunity. In this study, we analyze the expression of RAB27A and RAB27B in patients after pancreatic cancer surgery with or without adjuvant chemotherapy and its influence on overall survival. We analyzed a total of 167 patients with pancreatic cancer for their RAB27A and RAB27B expression. We dichotomized the patients along the median and compared survival in patients with high and low RAB27A and RAB27B expression with or without adjuvant chemotherapy treatment. We found a significant improvement in overall survival in patients with a negative resection margin (p= 0.037) and in patients who received adjuvant chemotherapy (p= 0.039). The survival benefit after chemotherapy was dependent on RAB27B expression status: only the subgroup of patients with high RAB27B expression benefited from adjuvant chemotherapy (p= 0.006), but not the subgroup with low RAB27B expression (p= 0.59). Patients with high RAB27B expression who did not receive adjuvant chemotherapy showed a trend towards worse survival compared to the other subgroups. This difference was abolished after treatment with adjuvant chemotherapy. These results suggest that RAB27B expression in pancreatic cancer might identify a subgroup of patients with poor survival who might respond well to adjuvant chemotherapy. If resectable, these patients could be considered for neoadjuvant chemotherapy to minimize the risk of not receiving adjuvant chemotherapy. Further prospective studies are needed to confirm these findings.
Sections du résumé
BACKGROUND
BACKGROUND
Pancreatic cancer is the 4th leading cause of cancer-related death with poor survival even after curative resection. RAB27A and RAB27B are key players in the exosome pathway where they play important roles in exosome secretion. Evidence suggests that RAB27A and RAB27B expression not only leads to tumor proliferation and invasion, but also plays an important role in antigen transfer necessary for anticancer immunity.
OBJECTIVE
OBJECTIVE
In this study, we analyze the expression of RAB27A and RAB27B in patients after pancreatic cancer surgery with or without adjuvant chemotherapy and its influence on overall survival.
METHODS
METHODS
We analyzed a total of 167 patients with pancreatic cancer for their RAB27A and RAB27B expression. We dichotomized the patients along the median and compared survival in patients with high and low RAB27A and RAB27B expression with or without adjuvant chemotherapy treatment.
RESULTS
RESULTS
We found a significant improvement in overall survival in patients with a negative resection margin (p= 0.037) and in patients who received adjuvant chemotherapy (p= 0.039). The survival benefit after chemotherapy was dependent on RAB27B expression status: only the subgroup of patients with high RAB27B expression benefited from adjuvant chemotherapy (p= 0.006), but not the subgroup with low RAB27B expression (p= 0.59). Patients with high RAB27B expression who did not receive adjuvant chemotherapy showed a trend towards worse survival compared to the other subgroups. This difference was abolished after treatment with adjuvant chemotherapy.
CONCLUSION
CONCLUSIONS
These results suggest that RAB27B expression in pancreatic cancer might identify a subgroup of patients with poor survival who might respond well to adjuvant chemotherapy. If resectable, these patients could be considered for neoadjuvant chemotherapy to minimize the risk of not receiving adjuvant chemotherapy. Further prospective studies are needed to confirm these findings.
Identifiants
pubmed: 37248891
pii: CBM220460
doi: 10.3233/CBM-220460
pmc: PMC10473075
doi:
Substances chimiques
rab GTP-Binding Proteins
EC 3.6.5.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
207-215Références
Med Oncol. 2015 Jan;32(1):372
pubmed: 25428385
Nat Med. 2007 Jan;13(1):54-61
pubmed: 17187072
Lancet. 2002 Jul 27;360(9329):295-305
pubmed: 12147373
Cancer Res. 2014 Oct 15;74(20):5758-71
pubmed: 25261234
Nat Med. 2001 Mar;7(3):297-303
pubmed: 11231627
Ann Surg. 2014 Aug;260(2):372-7
pubmed: 24374509
Ann Surg. 2021 Nov 1;274(5):713-720
pubmed: 34334656
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Nat Med. 2012 Mar 06;18(3):344-6; author reply 346
pubmed: 22395693
J Mol Med (Berl). 2013 Apr;91(4):431-7
pubmed: 23519402
Discov Med. 2015 Dec;20(112):357-67
pubmed: 26760980
Exp Cell Res. 2013 Jul 15;319(12):1706-1713
pubmed: 23092844
Curr Opin Cell Biol. 2010 Aug;22(4):461-70
pubmed: 20466531
Oncogene. 2020 Mar;39(13):2643-2657
pubmed: 32001818
Cancer Res. 2012 Oct 1;72(19):4920-30
pubmed: 22865453
Nat Cell Biol. 2010 Jan;12(1):19-30; sup pp 1-13
pubmed: 19966785
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Sci Rep. 2020 Aug 24;10(1):14136
pubmed: 32839520
APMIS. 2014 Nov;122(11):1080-7
pubmed: 24673604
Nat Med. 2009 Oct;15(10):1170-8
pubmed: 19767732
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
Biomark Med. 2019 Mar;13(4):239-247
pubmed: 30661368
Int J Oncol. 2017 Mar;50(3):920-932
pubmed: 28197629
Cancer Immunol Res. 2015 May;3(5):436-43
pubmed: 25941355
J Immunol. 2017 Nov 15;199(10):3559-3570
pubmed: 28978688
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Nature. 2018 Aug;560(7718):382-386
pubmed: 30089911
Lancet. 2020 Jun 27;395(10242):2008-2020
pubmed: 32593337
Cancer Discov. 2018 Sep;8(9):1069-1086
pubmed: 30115704
Pathology. 2001 Feb;33(1):21-5
pubmed: 11280603
Front Immunol. 2018 Apr 11;9:730
pubmed: 29696022
Clin Cancer Res. 2021 Dec 15;27(24):6761-6771
pubmed: 34593529
J Transl Med. 2012 Dec 05;10:242
pubmed: 23217148
Am J Pathol. 2019 Jan;189(1):44-57
pubmed: 30558722
Pancreas. 2016 Feb;45(2):204-10
pubmed: 26418905
Nat Med. 2007 Sep;13(9):1050-9
pubmed: 17704786
Nat Med. 2012 Jun;18(6):883-91
pubmed: 22635005
Nat Clin Pract Oncol. 2005 Aug;2(8):416-22
pubmed: 16130938
Cell. 2019 Apr 4;177(2):414-427.e13
pubmed: 30951669
Pancreas. 2017 Oct;46(9):1173-1179
pubmed: 28902788
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140